60 Degrees Pharmaceuticals Announces $4M Private Placement For The Issuance And Sale Of 2,898,551 Shares Of Its Common Stock, Series A Warrants To Purchase Up To 2,898,551 Shares Of Common Stock And Short-Term Series B Warrants To Purchase Up To...
60 Degrees Pharmaceuticals Announces $4M Private Placement For The Issuance And Sale Of 2,898,551 Shares Of Its Common Stock, Series A Warrants To Purchase Up To 2,898,551 Shares Of Common Stock And Short-Term Series B Warrants To Purchase Up To...
60 Degrees Pharmaceuticals Announces $4M Private Placement For The Issuance And Sale Of 2,898,551 Shares Of Its Common Stock, Series A Warrants To Purchase Up To 2,898,551 Shares Of Common Stock And Short-Term Series B Warrants To Purchase Up To 2,898,551 Shares Of Common Stock At A Purchase Price Of $1.38 Per Share
60 Degrees Pharmaceuticals宣佈進行400萬美元的定向增發，發行和銷售2,898,551股普通股、購買最多2,898,551股普通股的A系列認股權證和購買最多2,898,551股普通股的短期B系列認股權證，每股購買價格爲1.38美元。
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW))))) ("60P" or the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,898,551 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to purchase up to 2,898,551 shares of common stock and short-term series B warrants to purchase up to 2,898,551 shares of common stock at a purchase price of $1.38 per share (or per common stock equivalent in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants will have an exercise price of $1.38 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the warrants (the "Stockholder Approval"). The series A warrants will expire five years from the Stockholder Approval and the short-term series B warrants will expire eighteen months from the Stockholder Approval. The closing of the offering is expected to occur on or about September 5, 2024, subject to the satisfaction of customary closing conditions.
60 Degrees Pharmaceuticals, Inc.（納斯達克代碼：SXTP，SXTPW）（「60P」或「公司」）是一家專注於開發治療傳染病新藥的製藥公司，今日宣佈已簽署確定性協議，以價格市場化的方式進行私募定向增發，發行和銷售總計2,898,551股普通股（或一定數量普通股等價物）、購買最多2,898,551股普通股的A系列認股權證和購買最多2,898,551股普通股的短期B系列認股權證，每股購買價格爲1.38美元（或一定數量普通股等價物），並附帶認股權證。A系列認股權證和短期B系列認股權證的行權價格爲1.38美元，可在股東對行權的普通股股票發行事項的有效日期（「股東批准」）之日起行權。A系列認股權證將在股東批准之日起五年後到期，短期B系列認股權證將在股東批准之日起十八個月後到期。預計該發行將於2024年9月5日或約定的交割條件滿足時結束。
H.C. Wainwright & Co. is acting as the exclusive placement agent for the private placement.
H.C. Wainwright & Co.充當該私募定向增發的獨家放置代理人。
The gross proceeds to 60P from the offering are expected to be approximately $4 million, before deducting the placement agent's fees and other offering expenses payable by 60P, and excluding the proceeds, if any, from the exercise of the warrants. 60P intends to use the net proceeds from the offering for working capital, general operations, commercialization activities related to Arakoda, and the Company's research and development program.
預計此次發行將爲60P帶來約400萬美元的募集淨收益，扣除放置代理商費用和60P支付的其他發行費用，不包括認股權證的收益（如有）。60P擬將此次募集淨收益用於營運資金、一般運營、Arakoda的商業化活動以及公司的研發計劃。
譯文內容由第三人軟體翻譯。
